McKesson Corp stock (US58155Q1031): trading near highs as investors digest latest earnings and valuation metrics

McKesson Corp shares remain close to record territory after the US healthcare distributor reported higher profit for its fiscal fourth quarter ended 03/31/2025, leaving investors focused on the stock’s valuation multiples and income profile.

McKesson Corp shares are holding near recent highs on the New York Stock Exchange after the US healthcare distributor reported higher profit for its fiscal fourth quarter ended 03/31/2025, underscoring continued demand in its pharmaceuticals and medical products network, according to the company’s earnings release dated 05/07/2025 and coverage from Reuters on the same day.

The stock traded at about USD 675 on 06/05/2025 on the NYSE, leaving it close to its 52-week high and reflecting ongoing interest from investors in large US healthcare distributors, according to NYSE pricing data and Reuters quotes as of 06/05/2025.

As of: 05.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: MCK
• Sector/industry: Healthcare distribution and services
• Headquarters/country: Irving, United States
• Core markets: United States and Canada
• Key revenue drivers: Distribution of branded and generic pharmaceuticals, specialty therapies, and medical-surgical products, plus related technology and healthcare services
• Home exchange/listing venue: New York Stock Exchange (MCK)
• Trading currency: USD

McKesson Corp: core business model

McKesson Corp focuses on large-scale distribution of pharmaceuticals and medical products and complements this with technology-enabled services that support pharmacies, hospitals, and other care providers across North America as key revenue sources.

Valuation metrics and multiples for McKesson Corp

With McKesson Corp shares near record levels, investors are increasingly looking at valuation ratios to gauge how the stock compares to the broader US healthcare group and to its own recent history, using publicly available data from NYSE and major financial information providers as of 06/05/2025.

Based on the fiscal year ended 03/31/2025, McKesson Corp’s results reported on 05/07/2025 show that the company continues to generate sizeable revenue and profit from its core distribution franchise, which feeds into earnings-per-share figures used in standard valuation metrics such as the price-to-earnings multiple and enterprise-value-based ratios, according to the company’s 05/07/2025 earnings release and accompanying presentation.

Conclusion

McKesson Corp shares are trading close to record territory after the fiscal fourth-quarter results to 03/31/2025 highlighted the continued resilience of its US-focused drug distribution platform. For investors, the current price level shifts attention toward valuation ratios and income characteristics rather than short-term news flow.

Against that backdrop, the stock’s position within the US healthcare distribution space and its role in supplying pharmaceuticals and medical products remain central factors for assessing how its earnings power may support present valuation multiples over time.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.